Printer Friendly

Linzess Irritable Bowel Syndrome Market Analysis and Forecast to 2023.

DALLAS, March 17, 2015 /PRNewswire/ -- adds "Linzess (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023" market research report provides detailed information on Linzess including product description, safety and efficacy profiles as well as a SWOT analysis.

Linzess (linaclotide) is indicated for the treatment of IBS-C in adults. This product was initially discovered by Ironwood Pharmaceuticals, and its development and commercialization were supported by a series of licensing agreements with Forest in the US, Almirall in the EU, and Astellas in Japan. As of November 2014, Linzess was in Phase III of development as a potential treatment for IBS-C in Japan, and is therefore not currently available in this market. Complete report is available at

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naE[macron]ve, one, with only a small number of pharmacotherapy indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.


* Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

* Detailed information on Linzess including product description, safety and efficacy profiles as well as a SWOT analysis.

* Sales forecast for Linzess for the top 7 countries from 2013 to 2023.

* Sales information covered for the US, France, Germany, Italy, Spain, the UK, and Japan.

Order a Purchase copy of this report @ is a premium report priced at US$3495 for a single user License.)

Reasons to buy

* Understand and capitalize by identifying products that are most likely to ensure a robust return.

* Stay ahead of the competition by understanding the changing competitive landscape for IBS.

* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.

* Make more informed business decisions from insightful and in-depth analysis of Linzess performance.

* Obtain sales forecast for Linzess from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, the UK, and Japan).

Explore more reports of gastrointestinal therapeutics at

Related reports on gastrointestinal therapeutics:

Amitiza (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

Amitiza (lubiprostone) is indicated for the treatment of IBS-C in women 18 years of age and older, but only in the US. This product was developed by Sucampo Pharmaceuticals and Takeda, and initially gained approval in the US in 2006 for the treatment of chronic idiopathic constipation (CIC) in adults. In 2008, Amitiza gained a label expansion from the Food and Drug Administration (FDA) for the treatment of IBS-C in women of 18 years of age and older. Complete report available at

Xifaxan (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

Xifaxan (rifaximin) was developed by Alfa Wassermann, and is currently approved for the treatment of hepatic encephalopathy and traveler's diarrhea in the US and 5EU, except in France. In 1996, Salix Pharmaceuticals gained the exclusive rights to Xifaxan in the US, and is currently developing this product for the treatment of patients with IBS-D (Salix Pharmaceuticals, 2014). Complete report available at

Lotronex (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

Lotronex (alosetron) is indicated for women with severe IBS-D who have chronic IBS, have had anatomic or biochemical abnormalities of the GI tract excluded, and have not responded adequately to conventional therapy. GlaxoSmithKline (GSK) initially introduced this product into the US market in February 2000. However, a few months later, in November 2000, the company decided to withdraw the drug due to it being linked with undesirable adverse effects, such as ischemic colitis (restricted blood flow to the colon), severe constipation, and three fatalities. Complete report available at

Eluxadoline (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

Eluxadoline is being developed for the treatment of IBS-D. As of October 2014, it had reached the Phase III stage of development, and also has been granted a Fast-Track designation by the FDA. Furiex Pharmaceuticals initially licensed eluxadoline from Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson[J&J]) for the development of the product. Subsequently, Furiex was fully-acquired by Actavis in July 2014 (Furiex Pharmaceuticals, press release, July 2, 2014). Complete report available at

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us:

G+ / Google Plus:



RSS / Feeds:

Contact: Ritesh Tiwari TX, Dallas North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas 75252 Tel: +1-888-391-5441
COPYRIGHT 2015 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Date:Mar 17, 2015
Previous Article:Invoice IT Joins New ServiceMax Marketplace to Provide Billing and Payment Collection.
Next Article:CH2M HILL's Global Rail Experts at Middle East Rail Conference 2015.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters